Aktsia Jazz Pharmaceuticals PLC (JAZZ) hind ja uudised

Sümbolid Sümbolid	Hind	Muutus	% muutus	Trend	Eelm. sulgemishind	Ava	Kõrge	Madal	Maht	Turu kapit.
SIXB Materials SIXB Materials	SIXB +0,25%	1 104,10	+2,73	+0,25%	—	1 101,37	1 103,63	1 105,31	1 091,41	—	—
SIXC Communications SIXC Communications	SIXC −1,50%	604,16	−9,19	−1,50%	—	613,35	613,35	613,35	601,49	—	—
SIXE Energy SIXE Energy	SIXE −0,09%	1 197,81	−1,02	−0,09%	—	1 198,83	1 199,68	1 199,75	1 182,41	—	—
SIXI Industrials SIXI Industrials	SIXI −0,88%	1 740,41	−15,54	−0,88%	—	1 755,95	1 754,06	1 756,03	1 734,69	—	—
SIXM Financials SIXM Financials	SIXM −0,64%	634,44	−4,07	−0,64%	—	638,51	637,41	637,41	633,05	—	—
SIXR Staples SIXR Staples	SIXR −0,31%	840,90	−2,62	−0,31%	—	843,52	843,35	846,40	837,93	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,38%	215,13	−0,82	−0,38%	—	215,95	215,95	216,84	215,06	—	—
SIXT Technology SIXT Technology	SIXT +2,86%	3 228,71	+89,80	+2,86%	—	3 138,91	3 189,30	3 230,85	3 174,76	—	—
SIXU Utilities SIXU Utilities	SIXU +0,16%	935,87	+1,50	+0,16%	—	934,37	934,72	938,26	927,50	—	—
SIXV Health care SIXV Health care	SIXV −1,37%	1 457,12	−20,31	−1,37%	—	1 477,43	1 474,12	1 474,12	1 451,80	—	—
SIXY Discretionary SIXY Discretionary	SIXY +0,83%	2 399,84	+19,65	+0,83%	—	2 380,19	2 389,34	2 403,04	2 380,47	—	—

JAZZ:NASDAQ

Jazz Pharmaceuticals PLC

196,52 $

−1,72%

(−3,44) 1 p

199,00 $

+1,26% (+2,48)

Enne avanemist

Suletud: 24. apr, 16:00:01 GMT −4 · USD

Kõik sümbolid

1 p

5 p

1 kuu

6 kuud

YTD

1 a

5 a

MAX

	Sümbol	Hind	Muutus	% muutus

Üksuse JAZZ põhistatistika genereerimine…

Ava

200,25 $

Kõrge

201,40 $

Madal

194,77 $

Turu kapit.

12,10 mld

Keskm. maht

896,32 tuh

Maht

659,00

52 näd kõrgeim

207,48 $

52 näd madalaim

97,50 $

Aktsiatulu

−5,87 $

Beeta

0,23

Käibivad aktsiad

61,56 mln

Töötajate arv

3 tuh

Seotud aktsiad

Bank of New York Mellon Corp

Uudised

Erinevatest veebiallikatest

Investing.com Canada

15 minuti eest

FDA accepts Jazz Pharma filing for Ziihera in gastric cancer By Investing.com

Stock Titan

29 minuti eest

Aug. 25 FDA decision set for Jazz's first-line HER2+ cancer combo

Profiil

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia

Teave üksuse Jazz Pharmaceuticals PLC kohta

TegevjuhtBruce C Cozadd

Töötajad2,89 tuh

Asutatud2003

Peakontorid-

Sektor-

Veebisaitjazzpharma.com

Kõik väärtused on valuutas USD	märts 2025	juuni 2025	sept 2025	dets 2025
Tulu	897,84 mln	1,05 mld	1,13 mld	1,20 mld
Omahind	74,74 mln	116,27 mln	128,88 mln	112,92 mln
Kogukulu	74,74 mln	116,27 mln	128,88 mln	112,92 mln
Teadus- ja arenduskulud	180,65 mln	189,97 mln	198,20 mln	172,66 mln
Kõik teadus- ja arenduskulud	-	-	-	-
Müügi-, üld- ja halduskulud	514,01 mln	358,40 mln	379,15 mln	418,46 mln
Tegevuskulu	849,11 mln	710,47 mln	745,72 mln	760,86 mln
Kõik tegevuskulud	923,85 mln	826,74 mln	874,60 mln	873,79 mln
Tegevustulu	−26,01 mln	218,97 mln	251,51 mln	324,14 mln
Muu tegevusväline tulu	-	-	-	-
EBT, sh ebatavalised üksused	−110,35 mln	−735,64 mln	8,99 mln	208,41 mln
EBT, v.a ebatavalised üksused	−80,47 mln	169,72 mln	202,99 mln	278,02 mln
Tulumaksukulu	−17,81 mln	−17,17 mln	−242,42 mln	4,96 mln
Kehtiv maksumäär	16,14%	2,33%	−2 697,20%	2,38%
Muud tegevuskulud	-	-	-	-
Netosissetulek	−92,54 mln	−718,47 mln	251,41 mln	203,45 mln
Puhaskasumi marginaal	−10,31%	−68,71%	22,33%	16,98%
Aktsiatulu	1,68	−8,25	8,13	6,64
Intressi- ja investeerimistulu	-	19,10 mln	18,60 mln	20,50 mln
Intressikulu	−53,71 mln	−66,46 mln	−67,18 mln	−65,91 mln
Netointressikulud	−53,71 mln	−47,36 mln	−48,58 mln	−45,41 mln
Kulum ja amortisatsiooni kulud	-	-	-	-
EBITDA	138,86 mln	392,98 mln	429,76 mln	503,31 mln
Kasum või kahjum varade müügist	-	-	-	-

AI genereeritud sisu võib sisaldada vigu. Lisateave

AbiSaada tagasisidetPrivaatsus Tingimused Lahtiütlus

Finance

Uuring